BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marzi A, Reynolds P, Mercado-Hernandez R, Callison J, Feldmann F, Rosenke R, Thomas T, Scott DP, Hanley PW, Haddock E, Feldmann H. Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge. EBioMedicine 2019;49:223-31. [PMID: 31631035 DOI: 10.1016/j.ebiom.2019.09.055] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 O'Donnell K, Marzi A. The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms. Expert Rev Vaccines 2020;19:267-77. [PMID: 32129120 DOI: 10.1080/14760584.2020.1738225] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Marzi A, Jankeel A, Menicucci AR, Callison J, O'Donnell KL, Feldmann F, Pinski AN, Hanley PW, Messaoudi I. Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease. Front Immunol 2021;12:774026. [PMID: 34777392 DOI: 10.3389/fimmu.2021.774026] [Reference Citation Analysis]
3 Grais RF, Kennedy SB, Mahon BE, Dubey SA, Grant-klein RJ, Liu K, Hartzel J, Coller B, Welebob C, Hanson ME, Simon JK. Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials. The Lancet Microbe 2021;2:e70-8. [DOI: 10.1016/s2666-5247(20)30198-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Bhatia B, Meade-White K, Haddock E, Feldmann F, Marzi A, Feldmann H. A live-attenuated viral vector vaccine protects mice against lethal challenge with Kyasanur Forest disease virus. NPJ Vaccines 2021;6:152. [PMID: 34907224 DOI: 10.1038/s41541-021-00416-2] [Reference Citation Analysis]
5 Vianello E, Gonzalez-dias P, van Veen S, Engele CG, Quinten E, Monath TP, Medaglini D, Santoro F, Huttner A, Dubey S, Eichberg M, Ndungu FM, Kremsner PG, Essone PN, Agnandji ST, Siegrist C, Nakaya HI, Ottenhoff THM, Haks MC, Agnandij ST, Ahmed R, Anderson J, Auderset F, Bejon P, Borgianni L, Brosnahan J, Ciabattini A, Engler O, Haks MC, Harandi AM, Heppner DG, Gerlini A, Huttner A, Kremsner PG, Medaglini D, Monath TP, Ndungu FM, Njuguna P, Ottenhoff THM, Pejoski D, Page M, Pozzi G, Santoro F, Siegrist C, Agnandij ST, Borgianni L, Ciabattini A, Dubey S, Eichberg M, Engler O, Ndong EP, Harandi AM, Gerlini A, Huttner A, Kremsner PG, Lumeka K, Medaglini D, Nakaya HI, Gonzales Dias Carvalho P, Ottenhoff THM, Pozzi G, Rothenberger S, Santoro F, Siegrist C, Vianello E, Nakka SS, Haks MC, van Veen S. Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study. The Lancet Microbe 2022;3:e113-23. [DOI: 10.1016/s2666-5247(21)00235-4] [Reference Citation Analysis]
6 Pinski AN, Messaoudi I. Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity. Curr Opin Virol 2021;51:179-89. [PMID: 34749265 DOI: 10.1016/j.coviro.2021.10.007] [Reference Citation Analysis]
7 Furuyama W, Shifflett K, Pinski AN, Griffin AJ, Feldmann F, Okumura A, Gourdine T, Jankeel A, Lovaglio J, Hanley PW, Thomas T, Clancy CS, Messaoudi I, O'Donnell KL, Marzi A. Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine. bioRxiv 2021:2021. [PMID: 33501447 DOI: 10.1101/2021.01.19.426885] [Cited by in Crossref: 7] [Article Influence: 7.0] [Reference Citation Analysis]
8 Furuyama W, Reynolds P, Haddock E, Meade-White K, Quynh Le M, Kawaoka Y, Feldmann H, Marzi A. A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades. NPJ Vaccines 2020;5:4. [PMID: 31934358 DOI: 10.1038/s41541-019-0155-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
9 Surtees R, Stern D, Ahrens K, Kromarek N, Lander A, Kreher P, Weiss S, Hewson R, Punch EK, Barr JN, Witkowski PT, Couacy-Hymann E, Marzi A, Dorner BG, Kurth A. Development of a multiplex microsphere immunoassay for the detection of antibodies against highly pathogenic viruses in human and animal serum samples. PLoS Negl Trop Dis 2020;14:e0008699. [PMID: 33095766 DOI: 10.1371/journal.pntd.0008699] [Reference Citation Analysis]
10 Saito T, Maruyama J, Nagata N, Isono M, Okuya K, Takadate Y, Kida Y, Miyamoto H, Mori-Kajihara A, Hattori T, Furuyama W, Ogawa S, Iida S, Takada A. A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses. Viruses 2020;12:E923. [PMID: 32842671 DOI: 10.3390/v12090923] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Furuyama W, Shifflett K, Pinski AN, Griffin AJ, Feldmann F, Okumura A, Gourdine T, Jankeel A, Lovaglio J, Hanley PW, Thomas T, Clancy CS, Messaoudi I, O'Donnell KL, Marzi A. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine. mBio 2022;:e0337921. [PMID: 35012339 DOI: 10.1128/mbio.03379-21] [Reference Citation Analysis]
12 de Sá Magalhães S, Keshavarz-Moore E. Pichia pastoris (Komagataella phaffii) as a Cost-Effective Tool for Vaccine Production for Low- and Middle-Income Countries (LMICs). Bioengineering (Basel) 2021;8:119. [PMID: 34562941 DOI: 10.3390/bioengineering8090119] [Reference Citation Analysis]
13 Kurup D, Fisher CR, Scher G, Yankowski C, Testa A, Keshwara R, Abreu-Mota T, Lambert R, Ferguson M, Rinaldi W, Ruiz L, Wirblich C, Schnell MJ. Tetravalent Rabies-Vectored Filovirus and Lassa Fever Vaccine Induces Long-term Immunity in Nonhuman Primates. J Infect Dis 2021;224:995-1004. [PMID: 33421072 DOI: 10.1093/infdis/jiab014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Pinski AN, Messaoudi I. To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity. Microorganisms 2020;8:E1473. [PMID: 32992829 DOI: 10.3390/microorganisms8101473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Ollmann Saphire E. A Vaccine against Ebola Virus. Cell 2020;181:6. [PMID: 32243796 DOI: 10.1016/j.cell.2020.03.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
16 Lundstrom K. Self-replicating vehicles based on negative strand RNA viruses. Cancer Gene Ther 2022. [PMID: 35169298 DOI: 10.1038/s41417-022-00436-7] [Reference Citation Analysis]
17 Santoro F, Donato A, Lucchesi S, Sorgi S, Gerlini A, Haks MC, Ottenhoff THM, Gonzalez-Dias P, Consortium VE, Consortium VE, Nakaya HI, Huttner A, Siegrist CA, Medaglini D, Pozzi G. Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine. Vaccines (Basel) 2021;9:67. [PMID: 33498214 DOI: 10.3390/vaccines9020067] [Reference Citation Analysis]